Citations

Clear

3030 citation(s) found for "Susan, M".

Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions
Kar, Siddhartha , Gayther, Simon A. , Goode, Ellen L. , Moysich, Kirsten B., Pearce, Celeste Leigh, Ramus, Susan J. , Schildkraut, Joellen M. , Sellers, Thomas A. , Berchuck, Andrew , Pharoah, Paul D.P. , Ramus, Susan J , Moysich, Kirsten , Kar, Siddhartha

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 14, 2017 | Volume: 27 | Issue: 4 | Pages: 395-404

10.1158/1055-9965.epi-17-0315 | PMID 28615364 Get It

Abstract In this review, we summarize current progress in the genetic epidemiology of epithelial ovarian cancer (EOC), focusing exclusively on elucidating the role of common germline genetic variation in conferring susceptibility to EOC. We provide an overview of the more than 30 EOC risk loci identified to date by genome-wide association studies (GWAS) and describe the contribution of large-scale, cross-cancer type, custom genotyping projects, such as the OncoArray and the Collaborative Oncological Gene-Environment Study, to locus discovery and replication. We discuss the histotype-specific nature of these EOC risk loci, pleiotropy, or overlapping genetic effects between EOC and other hormone-related cancer types, and the application of findings to polygenic risk prediction for EOC. The second part of the article offers a concise review of primarily laboratory-based studies that have led to the identification of several putative EOC susceptibility genes using common variants at the known EOC risk loci as starting points. More global biological insights emerging from network- and pathway-based analyses of GWAS for EOC susceptibility are also highlighted. Finally, we delve into potential future directions, including the need to identify EOC risk loci in non-European populations and the next generation of GWAS functional studies that are likely to involve genome editing to establish the cell type–specific carcinogenic effects of EOC risk variants Cancer Epidemiol Biomarkers Prev; 27(4); 395–404. ©2018 AACR. See all articles in this CEBP Focus section, “Genome-Wide Association Studies in Cancer.”
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
Link, Brian K. , Syrbu, Sergei , Thompson, Carrie A. , Farooq, Umar , Novak, Anne J. , Allmer, Cristine, Lunde, Julianne J. , Macon, William R. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Weiner, George J. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Farooq, Umar , Slager, Susan L. , Kay, Neil E. , Witzig, Thomas E. , Link, Brian K , Weiner, George , Syrbu, Sergei

Mayo Clinic

International Journal of Epidemiology | June 12, 2017 | Volume: 46 | Issue: 6 | Pages: 1753-1754i

10.1093/ije/dyx119 | PMID 29025017 Get It

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES
Wang, Y., Wang, S.S., Inwards, David J. , Rothman, Nathaniel , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Witzig, Thomas E. , Cozen, Wendy , Morton, Lindsay M. , Chanock, Stephen Jacob , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4 Get It

INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS
Fraser, Graeme , Brown, Jennifer R. , Byrd, John C. , Dilhuydy, M.S., Jaeger, Ulrich, Moreno, Carol , Chanan‐Khan, A.A., Mahler, Michelle, Salman, Mariya, Cheng, Minghua , Londhe, Anil, Ninomoto, Joi , Howes, Angela, James, Danelle F. , Kipps, Thomas J. , Coutré, Steven , Barrientos, Jacqueline C. , Barr, Paul M. , O’Brien, Susan , Hillmen, Peter , Cramer, Paula , Stilgenbauer, Stephan , Hallek, Michael

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 109-111

10.1002/hon.2437_99 Get It

GB VIRUS‐C (GBV‐C) INFECTION AND RISK OF LYMPHOMA: A CASE‐CONTROL STUDY FROM NORTH AMERICA
Allmer, Cristine, Xiang, Jinhua , Klinzman, Donna, Feldman, Anya, Nowakowski, Grzegorz S. , Liebow, Mark , Larson, Matthew , Call, Timothy G. , Famà, Angelo , Link, Brian K. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Stapleton, Jack T.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 55-56

10.1002/hon.2437_40 Get It

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
Ghesquières, Hervé , Nicolas‐Virelizier, Emmanuelle , Thompson, C., Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Steven M., Sarkozy, Clémentine , Link, Brian K. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 34-35

10.1002/hon.2437_15 Get It

Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia ( CLL ): a prospective cohort study
Chaffee, Kari G. , Call, Timothy G. , Achenbach, Sara J., Rabe, Kari G. , Strati, Paolo , Strati, Paolo , Parikh, Sameer A. , Kay, Neil E. , Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D.

Mayo Clinic

British Journal of Haematology | June 5, 2017 | Volume: 178 | Issue: 3 | Pages: 394-402

10.1111/bjh.14785 | PMID 28580636 Get It

Summary The ultimate cause of death for most patients with newly diagnosed chronic lymphocytic leukaemia ( CLL ) and its relationship to co‐morbid health conditions is poorly defined. We conducted a prospective cohort study that systematically followed 1143 patients diagnosed with CLL between June 2002 and November 2014. Comorbid health conditions at the time of CLL diagnosis and their relationship to survival and cause of death were evaluated. Collectively, 1061 (93%) patients had at least one co‐morbid health condition at the time of CLL diagnosis (median number 3). Despite this, 89% of patients had a low‐intermediate Charlson Comorbidity Index score ( CCI ) at diagnosis. After a median follow‐up of 6 years, 225 patients have died. Death was due to CLL progression in 85 (46%) patients, infection in 14 (8%) patients, other cancer in 35 (19%) patients and comorbid health conditions in 50 (27%) patients. Higher CCI score and a greater number of major comorbid health conditions at the time of CLL diagnosis was associated with shorter non‐ CLL specific survival, but not with shorter CLL ‐specific survival on multivariate analysis. In conclusion, CLL and CLL ‐related complications (infections and second cancers) are the overwhelming cause of death in patients with CLL , regardless of CCI score and number of comorbid health conditions at diagnosis.
Long‐Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative
Drieling, Rebecca L. , LaCroix, Andrea Z. , Beresford, Shirley A.A. , Boudreau, Denise M. , Chlebowski, Rowan T. , Ko, Marcia G., Heckbert, Susan R. , Kooperberg, Charles

Mayo Clinic

Journal of the American Geriatrics Society | May 29, 2017 | Volume: 65 | Issue: 9 | Pages: 1924-1931

10.1111/jgs.14911 | PMID 28555811 Get It

Objectives To examine the association between long‐term bisphosphonate use and fracture in older women at high risk of fracture. Design Retrospective cohort. Setting Women's Health Initiative. Participants Older women who reported at least 2 years of bisphosphonate use in 2008–09 (N = 5,120). Measurements Exposure data were from a current medications inventory. Outcomes (hip, clinical vertebral, wrist or forearm, any clinical fracture) were ascertained annually. Using multivariate Cox proportional hazards models, the association between duration of bisphosphonate use (3–5, 6–9, 10–13 years) and fracture was estimated, using 2 years as the referent group. Results On average participants were 80 years old and were followed for 3.7 ± 1.2 years. There were 127 hip, 159 wrist or forearm, 235 clinical vertebral, and 1,313 clinical fractures. In multivariate‐adjusted analysis, 10 to 13 years of bisphosphonate use was associated with higher risk of any clinical fracture than 2 years of use (hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.07–1.57). This association persisted in analyses limited to women with a prior fracture (HR = 1.30, 95% CI = 1.01–1.67) and women with no history of cancer (HR = 1.36, 95% CI = 1.10–1.68). The association of 10 to 13 years of use, compared with 2 years of use, was not statistically significant for hip (HR = 1.66, 95% CI = 0.81–3.40), clinical vertebral (HR = 1.65, 95% CI = 0.99–2.76), or wrist fracture (HR = 1.16, 95% CI = 0.67–2.00). Conclusion In older women at high risk of fracture, 10 to 13 years of bisphosphonate use was associated with higher risk of any clinical fracture than 2 years of use. These results add to concerns about the benefit of very long‐term bisphosphonate use.
Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Ayala, Ruben , Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | May 15, 2017 | Volume: 41 | Issue: 10 | Pages: 2426-2434

10.1007/s00268-017-4028-1 | PMID 28508237 Get It

AbstractAfter decades on the margins of primary health care, surgical and anaesthesia care is gaining increasing priority within the global development arena. The 2015 publications of the Disease Control Priorities third edition on Essential Surgery and the Lancet Commission on Global Surgery created a compelling evidenced‐based argument for the fundamental role of surgery and anaesthesia within cost‐effective health systems strengthening global strategy. The launch of the Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care in 2015 has further coordinated efforts to build priority for surgical care and anaesthesia. These combined efforts culminated in the approval of a World Health Assembly resolution recognizing the role of surgical care and anaesthesia as part of universal health coverage. Momentum gained from these milestones highlights the need to identify consensus goals, targets and indicators to guide policy implementation and track progress at the national level. Through an open consultative process that incorporated input from stakeholders from around the globe, a global target calling for safe surgical and anaesthesia care for 80% of the world by 2030 was proposed. In order to achieve this target, we also propose 15 consensus indicators that build on existing surgical systems metrics and expand the ability to prioritize surgical systems strengthening around the world.